Table 5.
Trial | Measure | Baseline | 0 h | 48 h | 1 Month | |
---|---|---|---|---|---|---|
Valls et al. (2016) [40] | TIMI (TMPG of 2–3) | ctr | 79% | |||
VC | 95% | |||||
p | <0.01 | |||||
TIMI (TMPG of 0–1) | ctr | 21% | ||||
VC | 5% | |||||
p | <0.01 | |||||
Basili et al. (2010) [43] | %△ cTFC | ctr | 40.2 | −23% | ||
(frames/s) | VC | 36.1 | −41% | |||
p | NS | <0.0001 | ||||
TIMI (TMPG < 2) | ctr | 89% | 32% | |||
VC | 86% | 4% | ||||
p | NS | <0.01 | ||||
TIMI (TMPG = 3) | ctr | 39% | ||||
VC | 79% | |||||
p | <0.01 | |||||
Gasparetto et al. (2005) [33] | sVCAM-1 | ctr | 1.44 ± 0.7 | 2.03 ± 0.5 | 2.13 ± 0.8 | |
(ug/mL) | VC | 1.53 ± 0.6 | 1.63 ± 0.7 | 1.86 ± 0.9 | ||
p | NS | <0.01 | NS |
All numbers represent means unless they are italicized, which indicate median. TIMI: Thrombolysis in Myocardial Infarction; TMPG: TIMI Myocardial Perfusion Grade; cTFC: TIMI Frame Counts; %△ cTFC: % changes of cTFC; sVCAM-1: soluble vascular adhesion molecule 1. Baseline shows the value before PCI and 0 h values were samples taken immediately after PCI.